Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $8.30, close to its 52-week low of $7.61.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.9% and a 50.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $21.25, implying a 156.0% upside from current levels. In a report issued on October 22, Roth Capital also maintained a Buy rating on the stock with a $18 price target.
.
See today’s analyst top recommended stocks >>
Based on Epizyme’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12 million and GAAP net loss of $29.13 million. In comparison, last year the company had a GAAP net loss of $37.6 million.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPZM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers
